EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy

Mayra Alejandra Mafla-España iD, María Dolores Torregrosa, Manel Beamud-Cortés, Lorena Bermell-Marco, José Rubio-Briones, Omar Cauli iD

Biomolecules · 2023

DOI: 10.3390/biom13111642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Mayra Alejandra Mafla-España und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nursing Department, University of Valencia, 46010 Valencia, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Frailty. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nursing Department of the University of Valencia, Valencia, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgen deprivation therapy (ADT) is a mainstay of prostate cancer in both adjuvant and palliative settings. Since androgens are crucial for functional status and psychological functions, we evaluated whether blood testosterone, androstenedione, or DHEA concentrations were associated with functional status and psychological alterations in patients with localised (PCa) or metastatic prostate cancer (mPCa) receiving ADT with analogues of luteinising hormone-releasing hormone (LHRH).

Methods

The five Fried criteria were considered to identify frailty syndrome. In addition, complementary evaluations were carried out to measure other variables of interest. Sleep quality was assessed using the Athens Insomnia Scale, cognitive functions were assessed using the Mini-Mental State Examination, and symptoms of depression were measured using the Yesavage Geriatric Depression Scale. Logistic regression analysis was performed to determine if the androgens level could be related to frailty syndrome, sleep impairment, depressive symptoms, and cognitive functions.

Results

The results of the multivariate analyses show that high concentrations of androstenedione were significantly associated with frailty syndrome in both groups (p = 0.018; odds ratio = 4.66, 95% confidence interval [1.30–16.6]). There were significant relationships between frailty syndrome and the systemic concentration of androstenedione (p = 0.01), but not the concentration of testosterone (p = 0.60) or DHEA (p = 0.42). In addition, the results of the non-parametric tests show significant results between a decreased gait speed in the two groups (metastatic and localised) and the concentration of androstenedione (p = 0.015). High androstenedione levels were associated with a slow walking speed in the mCaP group (p = 0.016), while high testosterone levels were associated with a better walking speed in the localised CaP group (p = 0.03). For the concentration of androstenedione in plasma, the area under the curve was 0.72, with a 95% CI of 0.55–0.88 with acceptable values, and with a cut-off point of 4.51 pg/mL, a sensitivity of 82.9%, and specificity of 53.8%. No relationships between the concentration of androgens in plasma and sleep quality, cognitive functions, or symptoms of depression suggest that the changes were specific to frailty syndrome.

Conclusions

Further research into the role of androstenedione should be evaluated in follow-up studies in order to recommend its use as a suitable biomarker of frailty syndrome in prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsFrailtyMaleAgedHumansAndrogensAndrostenedioneAndrogen AntagonistsFrail ElderlyTestosteroneDehydroepiandrosterone

Stichwörter der Autor:innen

DHEALHRH analoguesandrostenedionefrailty syndromegeriatric assessmentlocalised prostate cancermetastatic prostate cancertestosterone

Substanzen

AndrogensAndrostenedioneAndrogen AntagonistsTestosteroneDehydroepiandrosterone

Autor:innen und Institutionen

  • Nursing Department, University of Valencia, 46010 Valencia, Spain.
  • Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain.
  • Medical Oncology Department, Doctor Peset University Hospital, 46017 Valencia, Spain.
  • Urology Department, Doctor Peset University Hospital, 46017 Valencia, Spain.
  • Urology Clinic, Hospital VITHAS 9 de Octubre, 46015 Valencia, Spain.
  • Chair of Healthy, Active and Participative Ageing, University of Valencia, 46010 Valencia, Spain.

ORCID-Profile: Mayra Alejandra Mafla-España, Omar Cauli

Förderung

  • Nursing Department of the University of Valencia, Valencia, Spain

Zitieren

APA

Mafla-España, M. A., Torregrosa, M. D., Beamud-Cortés, M., Bermell-Marco, L., Rubio-Briones, J., & Cauli, O. (2023). Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy. Biomolecules. https://doi.org/10.3390/biom13111642

Vancouver

Mafla-España MA, Torregrosa MD, Beamud-Cortés M, Bermell-Marco L, Rubio-Briones J, Cauli O. Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy. Biomolecules. 2023. doi:10.3390/biom13111642

BibTeX
@article{MaflaEspaa2023,
  author = {Mafla-España, Mayra Alejandra and Torregrosa, María Dolores and Beamud-Cortés, Manel and Bermell-Marco, Lorena and Rubio-Briones, José and Cauli, Omar},
  title = {Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13111642}
}
Kostenlos starten →